Lilly expands Insilico collaboration in deal worth up to $2.75 billion
Eli Lilly and Co. expanded its collaboration with Hong-Kong listed Insilico Medicine Inc. in a deal worth up to $2.75 billion. The move deepens Lilly's investment in artificial intelligence-driven drug discovery and could broaden its reach into next-generation metabolic therapies.
Eli Lilly and Co. is deepening its investment in artificial intelligence-driven drug discovery through a multibillion-dollar expansion of its collaboration with Hong-Kong listed Insilico Medicine Inc. The deal is worth up to $2.75 billion and could broaden Lilly's reach into next-generation metabolic therapies.
The expanded collaboration centers on artificial intelligence-driven drug discovery and pipeline expansion options. The move could broaden Lilly's reach into next-generation metabolic therapies.